Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3
The experimentally established mechanism targets of Racepinephrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 7/20 | 1.00 |
| ▸ | ADRB1 known ✓ | P08588 | 6/20 | 0.96 |
| ▸ | ADRB3 known ✓ | P13945 | 5/20 | 0.96 |
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.96 |
| ▸ | ADRA2B known ✓ | P18089 | 3/20 | 0.96 |
| ▸ | ADRA2C known ✓ | P18825 | 3/20 | 0.96 |
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 0.96 |
| ▸ | ADRA1B known ✓ | P35368 | 3/20 | 0.96 |
| ▸ | ADRA1D known ✓ | P25100 | 2/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 1.00 |
| ▸ | BLM | P54132 | 5/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.96 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.96 |
| ▸ | MAPT | P10636 | 6/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.96 |
| ▸ | TSHR | P16473 | 5/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.96 |
| ▸ | MEN1 | O00255 | 3/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Racepinephrine SCHEMBL16667632 | 1.00 | KDM4E (1.00) | KDM4EADRB2BLMPMP22NPSR1 | |
| Racepinephrine SCHEMBL31238229 | 1.00 | KDM4E (1.00) | KDM4EADRB2BLMPMP22NPSR1 | |
| Racepinephrine SCHEMBL9614373 | 1.00 | KDM4E (1.00) | KDM4EADRB2BLMPMP22NPSR1 | |
| Epinephrine SCHEMBL31267207 | 1.00 | KDM4E (1.00) | KDM4EADRB2BLMPMP22NPSR1 | |
| Epinephrine SCHEMBL4980185 | 1.00 | KDM4E (1.00) | KDM4EADRB2BLMPMP22NPSR1 | |
| Epinephrine SCHEMBL25041 | 1.00 | KDM4E (1.00) | KDM4EADRB2BLMPMP22NPSR1 | |
| L-Adrenaline SCHEMBL4983607 | 1.00 | KDM4E (1.00) | KDM4EADRB2BLMPMP22NPSR1 | |
| Racepinephrine SCHEMBL28311143 | 0.98 | KDM4E (0.96) | KDM4EADRB2BLMPMP22NPSR1 | |
| Epinephrine SCHEMBL3111795 | 0.98 | KDM4E (0.96) | KDM4EADRB2BLMPMP22NPSR1 | |
| Epinephrine SCHEMBL660960 | 0.98 | KDM4E (0.96) | KDM4EADRB2BLMPMP22NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3706 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122005425-A | Epinephrine soluble microneedle, preparation method and application thereof, and transdermal patch | 北京医院 | 2026-05-12 | — | — | CN | claimed |
| US-12409155-B1 | Ready to use LET formulations | QuVa Pharma Inc. (US) | 2025-09-09 | — | — | US | claimed |
| US-20250262173-A1 | INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS OF USE | RA CAPITAL AGENCY SERVICES, LLC, AS ADMINISTRATIVE AGENT FOR THE SECURED PARTIES | 2025-08-21 | — | — | US | claimed |
| CN-119792195-A | An epinephrine hydrochloride injection without antioxidant and its preparation method | 遂成药业股份有限公司 | 2025-04-11 | — | — | CN | claimed |
| CN-119662524-A | Keratin 15 type hair follicle stem cell culture medium, and adherence culture method and application | 艾斯生物医药(绍兴)有限公司 | 2025-03-21 | — | — | CN | claimed |
| CN-119504453-A | New preparation method of isoprenaline hydrochloride | 华仁医学研究(安徽)有限公司 | 2025-02-25 | — | — | CN | claimed |
| CN-115825281-B | Curcuma wenyujin and vinegar product quality evaluation method thereof | 南京中医药大学 | 2024-12-20 | — | — | CN | claimed |
| CN-119040983-A | Ultrafast preparation method and application of metal organic framework film based on additive | 天津大学 | 2024-11-29 | — | — | CN | claimed |
| CN-119033743-A | Epinephrine composition and application thereof | 马鞍山丰原制药有限公司 | 2024-11-29 | — | — | CN | claimed |
| CN-119032900-A | Construction method and application of plateau qi deficiency and blood stasis syndrome animal model | 中国人民解放军军事科学院军事医学研究院 | 2024-11-29 | — | — | CN | claimed |
| CN-1171045-A | Compositions for treating hemorrhoids and methods of use thereof | WHITEHALL LAB LTD (GB) | 1998-01-21 | — | — | CN | claimed |
| EP-0785770-A1 | HEMORRHOIDAL COMPOSITIONS AND METHOD OF USE | Whitehall Laboratories Limited (GB) | 1997-07-30 | — | — | EP | claimed |
| US-5624962-A | FOR OPHTHALMIC, DERMATOLOGICAL AND BADY CAVITICAL USE | WAKAMOTO PHARMACEUTICAL CO., LTD. (JP) | 1997-04-29 | — | — | US | claimed |
| US-5563153-A | GEL CONSISTS OF TETRACAINE HYDROCHLORIDE, EPINEPHRINE HYDROCHLORIDE, COACAINE HYDROCHLORIDE AND ABSORBABLE GELATIN STERILE POWDER | UNIVERSITY OF KANSAS MEDICAL CENTER (US) | 1996-10-08 | — | — | US | claimed |
| WO-1996017621-A1 | CORRECTING BIOLOGICAL INFORMATION TRANSFER USING THREE BIOLOGICAL INFORMATION BLOCKS | DNS SCIENTIFIC, INC. (US) | 1996-06-13 | — | — | WO | claimed |
| WO-1996014828-A1 | HEMORRHOIDAL COMPOSITIONS AND METHOD OF USE | WHITEHALL LABORATORIES LIMITED (GB) | 1996-05-23 | — | — | WO | claimed |
| EP-0694310-A1 | REVERSIBLE, THERMALLY GELLING WATER-BASE MEDICINAL COMPOSITION | Wakamoto Pharmaceutical Co., Ltd. (JP) | 1996-01-31 | — | — | EP | claimed |
| CN-1097593-A | Aqueous drug composition having property of reversible thermosetting gelation | WAKAMOTO PHARMA CO LTD (JP) | 1995-01-25 | — | — | CN | claimed |
| CN-1093897-A | The preparation method of surface anesthesia film | MENG LIJUN (CN) | 1994-10-26 | — | — | CN | claimed |
| US-4275074-A | Catecholamine treatment of ocular hypertension | Dobbie, Graham J. (US) | 1981-06-23 | — | — | US | claimed |